Silyl nitronates and nitrile oxides in organic synthesis. A novel route to d,l-deoxysugars. Use of aluminum oxide as solid phase base for generation of
作者:K.B.G. Torssell、A.C. Hazell、R.G. Hazell
DOI:10.1016/s0040-4020(01)91358-4
日期:1985.1
to a diene. 2. Stereospecific hydroxylation of the double bond. 3. Unmasking of the aldol moiety by catalytic reduction of the 2-isoxazoline. The syntheses of D,L-deoxyribose, D,L-oleose, D,L-digitoxose, D,L-2-deoxygalactose, 1,3-dideoxyfructose, 3-deoxyfructose etc. are described. Basic aluminum oxide is introduced as a solid phase base for the one step synthesis of 2-isoxazolines from aldoximes and
[EN] BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT BRM ET PROCÉDÉS D'UTILISATION ASSOCIÉS
申请人:PRELUDE THERAPEUTICS INC
公开号:WO2021252666A1
公开(公告)日:2021-12-16
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
本公开提供了具有靶蛋白结合基团和E3泛素连接酶结合基团的双功能化合物,以及相关的使用方法。
INHIBITORS OF D-AMINO ACID OXIDASE
申请人:Heffernan Michele L. R.
公开号:US20100029737A1
公开(公告)日:2010-02-04
The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.
BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
申请人:Prelude Therapeutics, Incorporated
公开号:US20220033409A1
公开(公告)日:2022-02-03
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.